Metastatic Malignant Solid Neoplasm Clinical Trials

163 clinical trials for Metastatic Malignant Solid Neoplasm across international registries, including 47 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers — RECRUITING · PHASE1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial — RECRUITING · PHASE2
• Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer — RECRUITING · PHASE1
• Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer — RECRUITING · PHASE1
• Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial — RECRUITING · PHASE2
• Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene — RECRUITING · PHASE1
• Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes — RECRUITING · PHASE1
• Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness — RECRUITING · PHASE1
• Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers — RECRUITING · PHASE1
• Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors — RECRUITING · PHASE1
• Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies — RECRUITING · PHASE1
• Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial — RECRUITING · PHASE2
• Imaging of Solid Tumors Using 18F-TRX — RECRUITING · PHASE1
• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer — RECRUITING · PHASE1
• PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer — RECRUITING · PHASE1
• TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma — RECRUITING · PHASE1
• Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer — RECRUITING · PHASE1
• Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations — RECRUITING · PHASE1
• Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning — RECRUITING · NA
• Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain — RECRUITING · PHASE3
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types — RECRUITING
• Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) — RECRUITING · PHASE2
• Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors — RECRUITING · PHASE1
• Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors — RECRUITING · PHASE1
• Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study — RECRUITING · PHASE4
• Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors — RECRUITING · PHASE2
• Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors — RECRUITING · PHASE2
• Group Cognitive Behavior Sessions (CBCSM) to Decrease Distress in Cancer Patients — RECRUITING · NA
• Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal — RECRUITING
• Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery — RECRUITING · NA
• Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers — RECRUITING · PHASE1
• Studying TAK-243 in Patients With Advanced Cancer — RECRUITING · PHASE1
• Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors — RECRUITING · PHASE2
• Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial — RECRUITING · NA
• SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial — RECRUITING · PHASE2
• MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers — RECRUITING · PHASE1
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors — RECRUITING · PHASE1
• Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial — RECRUITING · PHASE1
• Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform — RECRUITING
• Collection and Storage of Tissue and Blood Samples From Patients With Cancer — RECRUITING
• Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis — RECRUITING · NA
• Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) — RECRUITING · PHASE1
• Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases — RECRUITING · PHASE1
• Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases — RECRUITING · PHASE1
• Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tumors — RECRUITING · NA
• Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations — ACTIVE_NOT_RECRUITING · PHASE2

Refine this search